Brand VerifiedAustralia

CSL Limited

CSL

CSL Limited is the undisputed global leader in blood plasma-derived biotherapies and the world's second-largest influenza vaccine manufacturer, founded in 1916 as the Commonwealth Serum Laboratories, headquartered in Melbourne, Australia. With annual revenue of US$15.558 billion, the company operates 300+ plasma collection centers across the US, Europe, and China, employing 29,904 people. CSL enjoys an unassailable competitive moat through vertical integration spanning raw plasma collection to finished biologic manufacturing.

Strengths: CSL Behring generated US$11.158 billion from blood plasma products—immunoglobulins, albumin, and coagulation factors—in categories where patient dependency is absolute and substitution impossible. The company's 300+ CSL Plasma centers in the US create a closed-loop supply chain that competitors cannot replicate without decades of investment. CSL Seqirus is the only manufacturer with both egg-based and cell-based production platforms at industrial scale, contributing US$2.166 billion in influenza vaccine revenue. Operating cash flow of US$3.561 billion funds aggressive expansion into iron deficiency and nephrology through CSL Vifor.

Weaknesses: Plasma collection cost inflation from US labor market pressures structurally compresses margins, as donor compensation expenses rise faster than product pricing. CSL's narrow therapeutic focus creates concentration risk absent the portfolio diversification of larger multinational competitors. CSL's narrow therapeutic focus creates concentration risk absent the portfolio diversification of larger MNCs like Pfizer or Sanofi in non-biologic segments. Currency headwinds from AUD appreciation against USD materially impact reported earnings, given the majority of revenue is denominated in US dollars while headquarters costs are in Australian dollars.

Business Nature

Vertically integrated biotherapeutic company with complete ownership of the plasma-to-product value chain. CSL controls 300+ plasma collection centers in the US, Europe, and China—the raw material gateway—coupled with industrial-scale fractionation and purification facilities in Germany Marburg, Australia Melbourne, and Switzerland Bern. This closed-loop model eliminates supply chain dependencies and creates an unbreachable moat against competitors who must purchase plasma on the open market at higher cost and lower reliability.

Core Business Areas

Blood Plasma Products — Core Business CSL Behring
• Immunoglobulins Privigen, Hizentra — primary immunodeficiency and autoimmune disease therapies
• Albumin Albuminex — critical care volume expander for shock, burns, and surgery
• Coagulation factors Beriate, Mononine — hemophilia A and B replacement therapies
• Alpha-1 antitrypsin Zemaira — genetic emphysema therapy
• Hereditary angioedema therapies Berinert, Haegarda — C1 esterase inhibitor replacement
Influenza Vaccines — CSL Seqirus
• Flucelvax — cell-culture-based quadrivalent influenza vaccine
• Afluria — egg-based seasonal influenza vaccine
Iron Deficiency & Nephrology — CSL Vifor
• Ferinject/Injectafer — intravenous iron for iron deficiency anemia
• Velphoro — phosphate binder for dialysis patients

Industry Rankings

8Top 10 Biological Products & Vaccines Companies

Brand

9Top 10 Biological Products & Vaccines Manufacturers & Suppliers

Mfr

Corporate Report

CSL Limited is an Australia-based global biotechnology company headquartered in Melbourne. Founded in 1916 as the Commonwealth Serum Laboratories, privatized in 1994, the company has evolved into the world's largest plasma-derived therapies manufacturer and second-largest influenza vaccine producer. Revenue of US$15.558 billion (FY2025), employing 29,904 people with 300+ plasma collection centers supplying raw material for life-saving biologic manufacturing.

Business Overview

CSL operates three synergistic business units: CSL Behring (blood plasma products, 72% of revenue), CSL Seqirus (influenza vaccines, 14%), and CSL Vifor (iron deficiency/nephrology, 14%). The Behring division is the economic engine—immunoglobulins for immunodeficiency, albumin for critical care, and coagulation factors for hemophilia represent therapies where patient dependency is absolute. CSL's unique competitive advantage is its ownership of 300+ CSL Plasma donor centers, creating a fully integrated supply chain that competitors cannot replicate without decades of investment and regulatory approvals.

Seqirus is the only manufacturer operating both egg-based and cell-culture-based influenza vaccine platforms at industrial scale, providing pandemic preparedness differentiation. CSL Vifor, acquired for US$11.7 billion, extends the portfolio into the adjacent and fast-growing nephrology and iron deficiency markets.

Key Strengths

The 300+ plasma centers create a raw material monopoly-like position—plasma cannot be synthesized and donor supply is the rate-limiting factor for the entire plasma therapeutics industry. US$3.561 billion operating cash flow funds aggressive R&D and bolt-on acquisitions. The dual-platform Seqirus influenza vaccine manufacturing model (egg + cell-culture) provides unique production flexibility. CSL Vifor's 30+ planned new product launches across iron deficiency and kidney disease markets represent significant near-term growth catalysts. The HAE franchise (Berinert/Haegarda) continues to benefit from strong clinical data and limited competition.

Challenges & Outlook

Plasma collection cost inflation from US wage pressures structurally compresses gross margins, as donor compensation trends upward faster than finished product pricing. The company's narrow therapeutic focus—concentrated in plasma and vaccines—limits portfolio diversification compared to diversified pharmaceutical giants. AUD/USD currency movements materially impact reported earnings given revenue is predominantly USD-denominated while headquarters costs are AUD-based. Integration risk from the Vifor acquisition remains as synergies are yet to be fully realized.

VerityRank Score

CSL Limited achieves a VerityRank Score of 89/100, reflecting unparalleled plasma collection infrastructure, unique dual-platform influenza vaccine manufacturing, and strong cash flow generation. The score is moderated by plasma collection cost inflation, narrow therapeutic focus, and currency exposure from the AUD/USD exchange rate.

VerityRank Score

89/ 100

Based on market presence, financial scale, operational capacity, and brand strength.

Quick Facts

Headquarters

Melbourne, Victoria, Australia

Founded

1916.0

Employees

29904.0

Factories

300+ plasma collection centers + major fractionation plants in Germany, Australia, Switzerland

Listing

Australian Securities Exchange (ASX)

Data Sources & Methodology

This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.

VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.

Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.

Key references: Official Website , CSL 2025 Annual Report | CSL FY2025 Results Presentation | CSL Behring Manufacturing Sites

Back to Rankings